The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
The Chinese medicine sector fluctuated and rebounded. Ling Rui Pharmaceutical surged 8% to a new high, Tongrentang raised 4% in the short term, and Shouxiangu, Furui shares, and Kunming Pharmaceutical Group had the highest gains.
Zhejiang Pharmaceutical (600216): Vitamin prices are picking up, business conditions are improving in 1Q24
The 2023 results were lower than our expectations. 1Q24 was in line with our expectations Zhejiang Pharmaceutical's 2023 revenue of 7.794 billion yuan, -4.0% year over year; net profit to mother was 465 million yuan, corresponding to profit of 0.48 yuan per share
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
China Resources Shuanghe (600062): Another success, great results, and steady infusions/formulations
Another good result was achieved under a high base. The large infusion/formulation was stable, with a target price of 25.74 yuan. The “purchase” of China Resources Shuanghe achieved revenue of 2.84 billion yuan (+2.3% yoy) in 1Q24, and a net profit of 420 million yuan to the mother
Haida Group (002311): Feed business volume is increasing, leading advantages continue to be demonstrated
Haida Group released its 23 annual report and 2014 quarterly report: the company achieved operating income of 116.12 billion yuan (+10.89% year over year) and net profit to mother of 2.74 billion yuan (-7.31% year over year). Earnings per share
Huadong Pharmaceutical (000963): Achieved a good start in the first quarter, R&D progress accelerated
Performance Overview On April 25, 2024, the company released its report for the first quarter of 2024. In the first quarter of 2024, the company achieved operating income of 10.411 billion yuan, an increase of 2.93% over the previous year; achieved net profit to mother8